Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BSI002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : MSD Global Health Innovation
Deal Size : $11.3 million
Deal Type : Series A Financing
Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines Faster
Details : The financing will enable Baseimmune to accelerate the development of its vaccine candidate BSI002. It is currently evaluated in preclinical stage for the treatment of COVID-19.
Product Name : BSI002
Product Type : Vaccine
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : BSI002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : MSD Global Health Innovation
Deal Size : $11.3 million
Deal Type : Series A Financing